Pharmaceutical

CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval

CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).

Jul 6, 2024 - 04:00
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

NN-6561 by Novo Nordisk for Metabolic Dysfunction-Associated Steatohepatitis (MA...

Next Article

CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoF...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Gate Neurosciences plans Phase II MDD trial with next-gen antidepressant

Gate Neurosciences plans Phase II MDD trial with next-g...

May 18, 2023

Lyme disease cases rise, but largely due to a change in data collection

Lyme disease cases rise, but largely due to a change in...

Feb 15, 2024

Intercept’s liver disease drug Ocaliva faces FDA approval delay

Intercept’s liver disease drug Ocaliva faces FDA approv...

Oct 20, 2024